Added to YB: 2025-10-10
Pitch date: 2025-10-08
QURE [bullish]
uniQure N.V.
+6.3%
current return
Author Info
Truffle Pigs, written by the co-founders of Kipps Capital, shares in-depth reports on companies they believe are significantly undervalued. Sign up for the newsletter.
Company Info
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States.
Market Cap
$3.6B
Pitch Price
$59.88
Price Target
300.00 (+400%)
Dividend
N/A
EV/EBITDA
-26.45
P/E
-15.04
EV/Sales
258.99
Sector
Biotechnology
Category
growth
uniQure’s AMT-130 Gene Therapy — Breakthrough Moment for Huntington’s Disease
QURE: AMT-130 achieved 75% slowing of Huntington's disease progression over 3 years (p=0.003), first therapy to meaningfully alter fatal disorder's course. FDA BLA filing Q1 2026, likely Priority Review + CNPV fast-track. $2.5M pricing x 6K patients = $15B market. Acquisition target at 3-5x peak revs implies $200-300/share vs current ~$4B valuation.
Read full article (9 min)